Expert Chemicals (India) Private Limited, the promoter of Wanbury , has confirmed that it did not create any encumbrance on its shareholding during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges, ensures compliance with disclosure norms regarding substantial acquisition of shares and takeovers.

The confirmation was provided under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Expert Chemicals (India) Private Limited stated that neither it nor any persons acting in concert with it created any direct or indirect encumbrance during the specified period. Furthermore, the entity confirmed that no new encumbrances were established other than those previously disclosed to the authorities.

The filing, dated April 6, 2026, was addressed to the Listing Departments of the National Stock Exchange of India Limited and BSE Limited, as well as Wanbury's Audit Committee. The communication was signed by Sunil Vasudev Kotyankar, Director of Expert Chemicals (India) Private Limited.

Wanbury Limited has successfully completed a quality inspection conducted by the Therapeutic Goods Administration (TGA) at its manufacturing facility located in Tanuku, Andhra Pradesh. The inspection outcome underscores the company's adherence to stringent international manufacturing standards at this site.

TGA Inspection and GMP Certification

Following the successful completion of the TGA inspection, Wanbury has been issued a GMP (Good Manufacturing Practice) certificate for its Tanuku facility. This certification is a key regulatory milestone, as it directly enables the shipment of additional pharmaceutical products to markets governed by TGA oversight.

The key details of the regulatory development are summarised below:

Compliance and Regulatory Standing

The TGA is the regulatory body responsible for overseeing therapeutic goods in Australia, and a successful inspection by this authority reflects Wanbury's commitment to meeting international quality benchmarks. The GMP certificate obtained as a result of this inspection permits the shipment of 3 more Active Pharmaceutical Ingredients (APIs) from the Tanuku facility.

Further reinforcing its regulatory standing, Wanbury continues to maintain CGMP compliance at the facility. CGMP standards are internationally recognised guidelines that ensure pharmaceutical products are consistently produced and controlled according to quality standards, covering all aspects of production from raw materials to finished goods.

Significance for API Operations

The addition of 3 more APIs cleared for shipment expands the range of products that Wanbury can supply from its Tanuku site to TGA-regulated markets. This development highlights the facility's capability to meet the quality requirements of a major international pharmaceutical regulatory authority, reinforcing its position as a compliant API manufacturing hub.